Thomas B Nutman Selected Research

Loiasis

10/2021	A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.
1/2021	IL-10 and Its Related Superfamily Members IL-19 and IL-24 Provide Parallel/Redundant Immune-Modulation in Loa loa Infection.
1/2021	Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa.
1/2017	Discovery of Specific Antigens That Can Predict Microfilarial Intensity in Loa loa Infection.
1/2017	Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
1/2015	Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to Loa-endemic areas.
1/2013	Nodding syndrome.
8/2011	Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia.
8/2004	Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen.
1/2003	Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas B Nutman Research Topics

Disease

130	Infections 06/2022 - 02/2002
41	Filarial Elephantiasis (Lymphatic Filariasis) 01/2022 - 01/2003
28	Onchocerciasis 01/2021 - 03/2002
14	Inflammation (Inflammations) 01/2021 - 11/2002
14	Tuberculosis (Tuberculoses) 01/2019 - 01/2006
12	Eosinophilia 10/2021 - 06/2003
12	Pulmonary Tuberculosis 01/2020 - 12/2012
12	Malaria 01/2019 - 07/2009
10	Loiasis 10/2021 - 01/2003
9	Coinfection 01/2020 - 07/2009
8	Lymphedema (Milroy Disease) 01/2020 - 03/2005
8	Latent Tuberculosis 01/2019 - 07/2009
8	Hypereosinophilic Syndrome (Loeffler Endocarditis) 12/2009 - 06/2003
7	Intestinal Volvulus (Volvulus) 01/2019 - 02/2002
7	Parasitic Diseases (Parasitic Disease) 01/2017 - 07/2003
5	Hypersensitivity (Allergy) 06/2022 - 04/2006
4	Strongyloidiasis 01/2022 - 10/2011
4	Type 2 Diabetes Mellitus (MODY) 01/2020 - 10/2013
4	Persistent Infection 12/2019 - 05/2003
4	Fibrosis (Cirrhosis) 05/2013 - 06/2003
3	Elephantiasis 03/2020 - 02/2003
3	Filariasis 01/2019 - 04/2006
3	Neoplasms (Cancer) 01/2018 - 04/2012
3	Asymptomatic Infections 10/2016 - 01/2012
3	Mansonelliasis 10/2009 - 01/2003
2	Nodding Syndrome 01/2021 - 01/2017
2	Bites and Stings (Sting) 01/2021 - 07/2016
2	Ascariasis 01/2019 - 10/2004
2	Latent Infection 01/2019 - 11/2014
2	Communicable Diseases (Infectious Diseases) 05/2017 - 12/2004
2	Neglected Diseases 05/2017 - 11/2016
2	Fever (Fevers) 01/2017 - 03/2002
2	Brain Diseases (Brain Disorder) 02/2016 - 09/2014
2	Tetanus 01/2016 - 05/2004
2	Measles 01/2016 - 01/2013
2	Lymph Node Tuberculosis (Scrofula) 09/2014 - 01/2013

Drug/Important Bio-Agent (IBA)

72	AntigensIBA 06/2022 - 01/2003
51	CytokinesIBA 01/2021 - 10/2004
19	Immunoglobulin G (IgG)IBA 01/2022 - 06/2002
19	Ivermectin (Mectizan)FDA Link 01/2021 - 03/2002
19	Interleukin-10 (Interleukin 10)IBA 01/2021 - 01/2006
16	AntibodiesIBA 01/2022 - 01/2003
15	Proteins (Proteins, Gene)FDA Link 02/2022 - 06/2004
15	VaccinesIBA 01/2019 - 02/2002
14	Immunoglobulin E (IgE)IBA 06/2022 - 02/2003
13	Interleukin-4 (Interleukin 4)IBA 01/2021 - 02/2004
11	AllergensIBA 01/2021 - 02/2003
11	AnthelminticsIBA 01/2020 - 01/2012
9	Biomarkers (Surrogate Marker)IBA 12/2020 - 07/2003
7	Interleukin-5 (Interleukin 5)IBA 10/2021 - 01/2006
7	ChemokinesIBA 01/2021 - 03/2012
7	Pharmaceutical PreparationsIBA 01/2018 - 04/2004
6	Messenger RNA (mRNA)IBA 02/2022 - 06/2005
6	EnzymesIBA 01/2022 - 03/2003
6	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2020 - 01/2012
5	ImmunosorbentsIBA 01/2022 - 03/2003
5	Interleukin-13IBA 01/2021 - 01/2006
5	InterleukinsIBA 01/2021 - 01/2006
5	Interleukin-2 (IL2)IBA 01/2018 - 04/2006
5	Tryptases (Tryptase)IBA 01/2018 - 11/2002
4	Diethylcarbamazine (Hetrazan)FDA Link 10/2021 - 03/2002
4	Interleukin-9 (Interleukin 9)IBA 01/2021 - 09/2013
4	LipopolysaccharidesIBA 01/2020 - 01/2012
4	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 01/2012
4	LuciferasesIBA 10/2018 - 08/2008
4	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 04/2005
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 01/2009
4	Imatinib Mesylate (Gleevec)FDA Link 09/2015 - 06/2003
3	LigandsIBA 11/2021 - 04/2006
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2021 - 10/2010
3	reslizumabIBA 10/2021 - 04/2004
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 01/2017
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 05/2013
3	Albendazole (Albenza)FDA Link 01/2020 - 08/2004
3	Biological ProductsIBA 01/2020 - 10/2013
3	Hemoglobins (Hemoglobin)IBA 01/2019 - 01/2012
3	Eosinophil-Derived NeurotoxinIBA 01/2018 - 06/2004
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2017 - 10/2010
3	Interleukin-17 (Interleukin 17)IBA 11/2014 - 01/2009
3	InterferonsIBA 11/2014 - 01/2006
3	Histamine (Histamine Dihydrochloride)FDA Link 04/2006 - 10/2004
2	Indicators and Reagents (Reagents)IBA 01/2022 - 01/2012
2	AngiopoietinsIBA 11/2021 - 10/2010
2	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2003
2	Doxycycline (Periostat)FDA LinkGeneric 03/2020 - 10/2009
2	AdipokinesIBA 01/2020 - 01/2019
2	Immunoglobulin A (IgA)IBA 01/2019 - 01/2016
2	Eosinophil Cationic ProteinIBA 01/2018 - 07/2005
2	Interleukin-27 (Interleukin 27)IBA 11/2017 - 09/2015
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2017 - 01/2009
2	AutoantibodiesIBA 01/2017 - 07/2007
2	RNA (Ribonucleic Acid)IBA 10/2016 - 03/2012
2	Heme Oxygenase-1IBA 09/2015 - 01/2013
2	interleukin-21 (interleukin 21)IBA 01/2014 - 01/2009

Therapy/Procedure

19	Mass Drug Administration 01/2021 - 08/2011
17	Therapeutics 01/2021 - 01/2003
5	Aftercare (After-Treatment) 10/2020 - 11/2002
3	Drug Therapy (Chemotherapy) 03/2020 - 07/2009
2	Glycemic Control 01/2019 - 11/2014
2	Immunomodulation 01/2017 - 05/2012